ZA933725B - Tablet formulation - Google Patents

Tablet formulation

Info

Publication number
ZA933725B
ZA933725B ZA933725A ZA933725A ZA933725B ZA 933725 B ZA933725 B ZA 933725B ZA 933725 A ZA933725 A ZA 933725A ZA 933725 A ZA933725 A ZA 933725A ZA 933725 B ZA933725 B ZA 933725B
Authority
ZA
South Africa
Prior art keywords
tablet formulation
formulation
tablet
Prior art date
Application number
ZA933725A
Inventor
Michael Myers
Seamus Mulligan
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of ZA933725B publication Critical patent/ZA933725B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA933725A 1992-05-28 1993-05-27 Tablet formulation ZA933725B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE921706 1992-05-28

Publications (1)

Publication Number Publication Date
ZA933725B true ZA933725B (en) 1993-12-15

Family

ID=11039662

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA933725A ZA933725B (en) 1992-05-28 1993-05-27 Tablet formulation

Country Status (3)

Country Link
JP (3) JPH0733645A (en)
GB (1) GB2267219B (en)
ZA (1) ZA933725B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011184461A (en) * 2000-02-28 2011-09-22 Takeda Chem Ind Ltd Compressed solid preparation
AU2017403655B2 (en) 2017-03-16 2021-11-18 Cosci Med-Tech Co. Ltd. Glucose pellet, and preparation method therefor and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418247B (en) * 1975-11-17 1981-05-18 Haessle Ab SET TO MAKE BODIES WITH REGULATED RELEASE OF AN ACTIVE COMPONENT
EP0013131A3 (en) * 1978-12-27 1981-01-07 Mundipharma A.G. Pharmaceutical composition in solid dosage form, and process for its production
EP0211991B1 (en) * 1982-07-08 1989-10-25 Ab Leo Substained release tablets and method for preparation thereof
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
SE8404467D0 (en) * 1984-09-06 1984-09-06 Ferrosan Ab CONTROLLED-RELEASE MEDICAL PREPARATIONS
NZ226575A (en) * 1987-10-16 1991-01-29 Elan Corp Plc Controlled release formulation containing cis-(+)-3-acetyloxy-5-(2-(dimethylamino)ethyl)-2,3 dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepine-4(5h)one(diltiazem) and having a surrounding membrane
JPH0791184B2 (en) * 1988-03-31 1995-10-04 田辺製薬株式会社 Controlled release formulation and process for producing the same
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JPH0717498B2 (en) * 1989-05-31 1995-03-01 興和株式会社 Antitussive expectorant soft capsule
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
DE9190107U1 (en) * 1990-08-07 1993-12-16 Pfizer Dispensing device with membranes obtained by interfacial polymerization

Also Published As

Publication number Publication date
JPH0733645A (en) 1995-02-03
GB9310954D0 (en) 1993-07-14
GB2267219B (en) 1996-04-03
JP2010209108A (en) 2010-09-24
JP2006001941A (en) 2006-01-05
GB2267219A (en) 1993-12-01

Similar Documents

Publication Publication Date Title
KR960009828B1 (en) Tablet device
PL299496A1 (en) Tablet dispenser
ZA923068B (en) Optimized tablet formulation
GB9114950D0 (en) Pharmaceutical formulation
HU9300804D0 (en) Pharmaceutical preparatives
GB2264383B (en) Display-intergrated tablet
GB9221883D0 (en) Novel formulation
GB9310954D0 (en) Tablet formulation
CA71188S (en) Tablet
ZA946797B (en) Stabilized tablet formulation
GB9323864D0 (en) Stabilized tablet formulation
GB9212968D0 (en) Pharmaceutical formulation
GB9221694D0 (en) Pharmaceutical formulation
CA70987S (en) Tablet case
CA70934S (en) Tablet case
CA70854S (en) Tablet case
CA70499S (en) Pharmaceutical tablet
GB9202110D0 (en) Formulation
ZA928061B (en) Lipomimetic formulation
GB9201915D0 (en) Formulation
GB9205183D0 (en) Formulation
GB9217322D0 (en) Formulation
GB9225583D0 (en) Formulation
CA69106S (en) Tablet
GB9305437D0 (en) Pharmaceutical formulation